John Carlo Trials transgender testing John Carlo Trials

HIV advocates hail new long-lasting PrEP option

Dr. John Carlo Trials of Cabotegravir so successful, GSK ends trials early Tammye Nash | Managing HIV Advocates this week applauded news of a new drug for use in pre-exposure prophylaxis regimens that has proven so successful in trials that the trials were ended early.

ViiV Healthcare — majority owned by GlaxoSmithKline with Pfizer Inc. and Shionogi Limited as shareholders — had been testing a new, long-lasting injectible PrEP drug called Cabotegravir.

All news from

The website is not a news writer, but just an aggregator. The site publishes announcements of the materials taken from the open sources. The news source is indicated at the beginning and at the end of the announcement. As a part of the fight against fakes, you can send a complaint on the news, and we will consider your complaint as soon as possible.

Related News

Breaking news
Da Palermo a Milano in piazza al grido di #spazzalodio. A manifestare anche Zan e Maiorino
Christina Perri reveals she's pregnant after a recent miscarriage: Our rainbow baby is coming in January
‘Hannibal’ season 4: creator teases pansexual Mads Mikkelsen in potential comeback